The recognition and management of pulmonary toxicity caused by immunotherapy is critical because cancer treatment paradigms have shifted and immunotherapy is more frequently used. Continued reports of pulmonary toxicity due to immunotherapy is essential to provide a comprehensive understanding of possible complications that providers need to be able to recognize and treat. Identifying toxicity quickly and treating patients appropriately will prevent morbidity and mortality in cancer patients treated with checkpoint inhibitors.
The authors acknowledge and thank the Department of Pulmonary Medicine at Marshall University for their help.
South Med J. 2020;113(11):600-605. © 2020 Lippincott Williams & Wilkins